

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/506,309	09/01/2004	Toru Yamano	3029 US0P	8326
23115 7	590 11/16/2005		EXAMINER	
TAKEDA PHARMACEUTICALS NORTH AMERICA, INC INTELLECTUAL PROPERTY DEPARTMENT			FREISTEIN, ANDREW B	
475 HALF DAY ROAD			ART UNIT	PAPER NUMBER
SUITE 500			1626	
LINCOLNSHI	RE, IL 60069		DATE MAIL ED. 11/1/2004	-

Please find below and/or attached an Office communication concerning this application or proceeding.

			
	Application No.	Applicant(s)	
Office Action Commons	10/506,309	YAMANO ET AL.	
Office Action Summary	Examiner	Art Unit	
	Andrew B. Freistein	1626	
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address	
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim rill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).	
Status			
1) ☐ Responsive to communication(s) filed on 13 Security 2a) ☐ This action is FINAL . 2b) ☐ This 3) ☐ Since this application is in condition for alloward closed in accordance with the practice under E	action is non-final. nce except for formal matters, pro		
Disposition of Claims			
4) □ Claim(s) 1-6 is/are pending in the application. 4a) Of the above claim(s) 6 is/are withdrawn fro 5) □ Claim(s) is/are allowed. 6) □ Claim(s) 1 is/are rejected. 7) □ Claim(s) 2-6 is/are objected to. 8) □ Claim(s) are subject to restriction and/or Application Papers 9) □ The specification is objected to by the Examine 10) □ The drawing(s) filed on is/are: a) □ access Applicant may not request that any objection to the ore Replacement drawing sheet(s) including the correction 11) □ The oath or declaration is objected to by the Examine 11) □ The oath or declaration is objected to by the Examine 11) □ The oath or declaration is objected to by the Examine 11) □ The oath or declaration is objected to by the Examine 11.	election requirement. r. epted or b) objected to by the Edrawing(s) be held in abeyance. See on is required if the drawing(s) is obj	e 37 CFR 1.85(a). ected to. See 37 CFR 1.121(d).	
Priority under 35 U.S.C. § 119			
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority documents 2. Certified copies of the priority documents 3. Copies of the certified copies of the prior application from the International Bureau * See the attached detailed Office action for a list of	s have been received. s have been received in Application ity documents have been received (PCT Rule 17.2(a)).	on No ed in this National Stage	
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date 9/1/2004.	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal Pa	(PTO-413) te atent Application (PTO-152)	

Art Unit: 1626

DETAILED ACTION

Claims 1-6 are currently pending in the instant application.

Priority

This application is a 371 of PCT/JP03/02563, filed 03/05/2003.

Acknowledgement is made of Applicant's claim for foreign priority under 35 U.S.C. § 119(a)-(d), by Japanese Patent Application No. 2002060402 filed on 03/06/2002.

Information Disclosure Statement

Applicant's information disclosure statement (IDS), filed on 09/01/2004, has been considered. Please refer to Applicant's copies of the 1449 submitted herewith.

Response to Restriction Requirement

Acknowledgement is made of Applicant's election of Group IV (with traverse) and the species of Examples 3 and 4 on pages 38-41 of the specification,

filed September 13, 2005.

Applicant traverses the restriction requirement, because there are limitations in the claims for the definitions of R^1 and R^2 . Applicant requests Groups IV and V be combined, because of the limitations of R^1 and R^2 .

Examiner agrees to combine the definitions of R³, R⁴ and R⁵ from Group IV and Group V (see Status of the Claims section below).

Application/Control Number: 10/506,309 Page 3

Art Unit: 1626

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.

Claims 1-6 are rejected under 35 U.S.C. 102(a) as being anticipated by Ojida, et al., "Highly Enantioselective Reformatsky Reaction of Ketones: Chelation-Assisted Enantioface Discrimination," <u>Organic Letters</u>, Vol. 4, No. 18, pp. 3051-3054 (2002).

Although the three inventors of the instant application are co-authors of the article (Akio Ojida, Toru Yamano, and Naochiro Taya), there is another author of the article (Akihiro Tasaka). As a result, the invention was "known or used by others" before the invention by the applicant. See MPEP § 2132.01(III) (" 'Others' means any combination of authors or inventors different than the inventive entity").

Claim 1 of the instant application claims a method for producing an optically

$$R^4$$
 R^5
HO $*$ CO_2R^3
 R^1 R^2 wherein

active β-hydroxy ester represented by formula (III),

R¹ is an optionally substituted aromatic group; R² is represented by formula (IV),

Art Unit: 1626

; L is a protecting group; R³ is a hydrocarbon group; and R⁴ and R⁵ are each hydrogen.

The method comprises reacting, in the presence of a cinchona alkaloid, a

compound of formula (I),
$$R^1 \longrightarrow R^2$$
, wherein R^1 and R^2 are as defined in

$$R^4$$
 R^5
 $X Zn CO_2R^3$

Formula (III) above, with a compound of formula (II), wherein R³, R⁴ and R⁵ are as defined in Formula (III) above.

The prior art Ojida, et al. article discloses a Reformatsky reaction used in a

presence of cinchonine. Additionally, basic additives were added to the reaction mixture in further experimentations (see p. 3052).

This rejection pursuant to 35 U.S.C. § 102(a) will be obviated by providing evidence of the date of the invention pre-dating the publication of Ojida, et al., such as a certified translation of the priority document (Japanese Patent

Art Unit: 1626

Application No. 2002060402); or alternatively, by providing a declaration that the Ojida, et al. article cited in the rejection was solely the work of the present inventors (Akio Ojida, Toru Yamano, and Naochiro Taya). See MPEP § 2132.01.


Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claim 1 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 1 defines R² as, "a nitrogen-containing heterocyclic group different from



R¹, which is represented by the general formula:

(V) wherein the

ring may be substituted, and may have one or more heteroatoms in addition to the nitrogen in the formula;..."

This definition is unclear, because it does not state how many atoms the nitrogen-containing heterocycle contains and what the additional heteroatoms are. From the drawing, it appears that there are a minimum of two carbon atoms and one nitrogen atom. However, the claim should be rewritten to state a minimum and a maximum range.

Art Unit: 1626


For example, the claim could be rewritten to state, "...a nitrogen-containing heterocyclic group of 5- to 6-members different from R¹, which is represented by the

$$\sqrt{N}$$

general formula:

(V) wherein the ring may be substituted, and may

have one or more heteroatoms **selected from N, O and S** in addition to the nitrogen in the formula;..." (emphasis added to highlight the proposed amendment).




Similarly, where R² is of formula (VI),

, it is unclear how

many atoms are in the nitrogen-containing heterocyclic group and what the additional heteroatoms are. This definition should be amended in a similar way to formula (V) above.

Additionally, Claim 1 is rejected, because of the definition of R², which states, "...provided that a case is eliminated where R¹ is an optionally substituted aromatic



group and R² is a group represented by the general formula:

wherein L represents a protecting group,..." (see claim 1, p. 2, lines 2-6). Specifically,

the language, "a case is eliminated" is ambiguous. It is unclear what "case" Applicant is

eliminates and under what circumstance the elimination occurs. The elimination proviso should be clearly identified rather than stated in general terms or deleted from the claim.

Claim 1 is also rejected for the improper definition of "cinchona alkaloid." It is defined in the specification only be examples and exemplification is not a specific definition (see specification, p. 16, lines 18-19). The specification must set forth the definition explicitly and clearly, with reasonable clarity, deliberateness and precision, Teleflex Inc. v. Ficosa North Am Corp., 63 USPQ2d 1374, (Fed. Cir. 2002), Rexnord Corp. v. Laitram Corp., 60 USPQ2d 1854 (Fed. Cir. 2001).

Claim 1 should be amended to incorporate the definitions of cinchona alkaloid of claim 4 into the claim 1. For example, in claim 1, page 2, line 16+ should be amended to read, "...in the presence of a cinchona alkaloid **selected from the group consisting of cinchonie, cinchonidine, quinine, or qunidine**, or a salt thereof..." (emphasis added to highlight the proposed amendment).

Status of the Claims

Claims 1-6 are currently pending in the instant application.

Claims 1 (in part) and 6 are withdrawn from further consideration by the Examiner as being drawn to non-elected inventions under 37 CFR § 1.142(b). The withdrawn subject matter is patentably distinct from the elected subject matter as it differs in structure and element and would require separate search considerations. In addition, a reference that anticipates one invention would not render obvious the other invention.

Art Unit: 1626

Elected and Examined Subject Matter

The scope of the invention of the elected subject matter and the examined subject matter is as follows:

A method for producing an optically active β-hydroxy ester represented by

formula (III),
$$R^4$$
 R^5 R^5 comprises reacting, in the presence of a

cinchona alkaloid, a compound of formula (I), $R^1 \longrightarrow R^2$, with a compound o

$$X \sim \frac{R^4}{Zn} R^5$$
 CO_2R^3
wherein

formula (II),

R¹ is an optionally substituted phenyl;

R² is a 5- to 6-membered nitrogen-containing aromatic heterocyclic group;

R³ is an optionally substituted hydrocarbon group;

R⁴ is H, an optionally substituted hydrocarbon group, or R⁴ is taken together with R⁵ to form a ring;

R⁵ is H, an optionally substituted hydrocarbon group, or R⁵ is taken together with R⁴ to form a ring; and

L is as defined in claim 1.

Art Unit: 1626

Non-elected and Non-examined Subject Matter

The scope of the invention of the non-elected and non-examined subject matter is as follows:

A method for producing an optically active β-hydroxy ester represented by

formula (III),
$$R^4$$
 R^5 R^5 comprises reacting, in the presence of a

cinchona alkaloid, a compound of formula (I), $R^1 \longrightarrow R^2$, with a compound o

$$X = \begin{bmatrix} R^4 & R^5 \\ X & CO_2R^3 \\ \text{formula (II),} \end{bmatrix}$$
, wherein

R¹ is hydrogen, an optionally substituted hydrocarbon group, or an optionally substituted heterocyclic group;

R² is a nitrogen-containing aromatic heterocyclic group that has less than five members or more than six members;

R³ is an optionally substituted heterocyclic group, or together with R⁴ or R⁵ forms a ring;
R⁴ is a halogen atom, an optionally substituted silyl group, or together with R³ forms a ring;

Art Unit: 1626

R⁵ is a halogen atom, an optionally substituted silyl group, or together with R³ forms a ring;

As a result of the election and the corresponding scope of the invention, identified supra, the remaining subject matter of Claim 1 and 6 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to non-elected inventions. The withdrawn compounds contain varying functional groups such as azepanyl, azetidinly, aziridine, indole, adnenine, etc. which are chemically recognized to differ in structure, function, and reactivity.

Therefore, the subject matter which was withdrawn from consideration as being non-elected subject matter materially differs in structure and composition from the elected/examined subject matter so that a reference which anticipates the elected/examined subject matter would not render obvious the non-elected subject matter.

Claim Objections

Claims 1 and 6 are objected to as being drawn to non-elected subject matter.

Claims 2-6 are objected to as being dependent upon a rejected base claim.

Telephone Inquiry

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Andrew B. Freistein whose telephone number is (571) 272-8515. The examiner can normally be reached Monday-Friday, 8:30 am - 5:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Joseph McKane can be reached on (571) 272-0699. The fax phone number for the organization where this application or proceeding is assigned is (571) 273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at (866) 217-9197 (toll-free).

KAMAL A. SAEED, PH.D. PRIMARY EXAMINER

Andrew B. Freistein Patent Examiner, AU 1626

Joseph K. McKane

Supervisory Patent Examiner, AU 1626

Date: November 7, 2005